News

“Insurance companies assert that restricting accumulator and maximizer programs will cause higher health insurance premiums for everyone, but that claim is false….

In this video, World Federation of Hemophilia (WFH) Director of Research and Education Donna Coffin talks about the new WFH shared decision-making…

NHF’s National Research Blueprint will ensure that lived experiences shape the future of bleeding disorders research and care. When it comes to…

Experts answer your most pressing questions about navigating the job market with a bleeding disorder. Nick McRae-Cyr knew he wouldn’t be going…

Break out of solitary habits with these strategies. As we grow older, we’re more likely to experience loneliness. Because of hearing loss,…

Cardiac care can be a delicate balancing act for people with bleeding disorders. The minute Pedro Estalilla came home from his job…

As we all know, the web is a pretty fast-moving place. In that fast-moving environment, GLHF likes to think that its website…

The US Food and Drug Administration (FDA) approved Roctavian, a one-time gene therapy for adults with severe hemophilia A who do not…

Reports from 26 States Show More than 1.5 M Beneficiaries Have Already Been Disenrolled. Wisconsin residents: Congress told states it was time…

An overview of the types of pain you might experience, what you can do to manage pain at home, and when to…

Concern grows over the mounting tally of Medicaid coverage losses impacting people who remain eligible for the program. Read how federal regulators…

The new approval will allow consumers to purchase this oral contraceptive medication without a prescription at stores and online. The U.S. Food…

This paper takes a broad, holistic view of patient safety in the era of hemophilia gene therapy. After several decades of preclinical…

Yesterday, the U.S. Food and Drug Administration approved Roctavian (valoctocogene roxaparvovec), the first gene therapy for hemophilia A. This new treatment option, for the treatment of…

Pivotal data from the Phase 3 XTEND-Kids study evaluating ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] once-weekly prophylaxis, a factor VIII replacement…

BioMarin Pharmaceutical Inc. today announced the U.S. Food and Drug Administration approved ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) gene therapy for the treatment of adults…

After several decades of preclinical and clinical research, pitfalls and progress, gene therapies for hemophilia A and B have become a reality…

that the call for applications for the Susan Skinner Memorial Fund (SSMF) Scholarship program is now open! Please spread the word among…

Early data on Medicaid “unwinding” shows an alarming rate of coverage losses for enrollees who may still be eligible. Colorado and Texas…

Is your camper prepared? Are you?It’s time to start preparing for Camp Klotty Pine as we count down the days to camp…

Authors of the review posit that reference intervals such as those utilized in thrombosis and hemostasis, are based on structural inequities. A…

HEMGENIX is indicated for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or…

Pfizer Inc. today announced their Phase 3 BASIS clinical trial evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and…

Hemophilia Federation of America has launched a new resource and search feature for clinical trials for patients with bleeding disorders.  “Patients and families have asked for…